Antinuclear Antibody Screen (ANA); Anti Strptolysin-O (ASO); Calcium (Ca); Chem 6 [Blood Urea Nitrogen (BUN); Creatinine; Electrolytes [ Carbon Dioxide (CO2); Chloride (CL); Potassium (K); Sodium (Na) ]; Complete Blood Count [ Automated Differential; Hematocrit (Hct); Hemoglobin (Hgb); Mean Corpuscular Hemoglobin (MCH); Mean Corpuscular Hemoglobin Concentration (MCHC); Mean Corpuscular Volume (MCV); Platelet (PLT); Red Blood Cell Count (RBC); Red Cell Distribution Width Standard Deviation (RDWSD); Red Cell Distribution Width Coefficient Variation (RDWCV); White Blood Cell Count (WBC)] ; C-Reactive Protein (CRP); Creatine Kinase (CK); Epstein-Barr Virus Basic Panel [Epstein-Barr Virus Antibody IgG; Epstein-Barr Virus Antibody IgM] ; Estrogen, Total; Glucose Random; HLA-B27 Antigen; Insulin - Like Growth Factor 1 (IGF-1 / Somatomedin C); Magnesium (Mg); Parathyroid Hormones Intact (PTH Intact); Progesterone; Protein Electrophoresis; Rheumatoid Factor (RF); Sedimentation Rate (ESR); Testosterone, Total; Thyroid Profile with TSH [Free Thyroxine Index (FTI); T3 Uptake; Thyroid Stimulated Hormone (TSH); Thyroxine Total (T4)]; Uric Acid
Athletes, like all others, may have illnesses or conditions that require them to take particular medications. If the medication an athlete is required to take to treat an illness or condition happens to fall under the prohibited list, a therapeutic use exemption may give that athlete the authorization to take the needed medicine. Criteria for granting a therapeutic use exemption are 1.) The athlete would experience significant health problems without taking the prohibited substance or method, 2.) The therapeutic use of the substance would not produce significant enhancement of performance, and 3.) There is no reasonable therapeutic alternative to the use of the otherwise prohibited substance or method. Note hormone replacement therapy (HRT), . supplementing with prescribed testosterone in any form to raise testosterone levels due to natural decreases that occur with aging (even if to just elevate levels to within ‘normal’ ranges), is NOT considered a medicinal exception. Persons using HRT would not be eligible for WPA/NANBF/IPE competition.
Finasteride was the first 5-ARI to be introduced for medical use.  It was marketed for the treatment of BPH in 1992 and was subsequently approved for the treatment of pattern hair loss in 1997.  Epristeride was the second 5-ARI to be introduced and was marketed for the treatment of BPH in China in 2000.  Dutasteride was approved for the treatment of BPH in 2001 and was subsequently approved for pattern hair loss in South Korea in 2009 and in Japan in 2015.   The patent protection on finasteride and dutasteride has expired and both drugs are available as generic medications .